The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | CARMEN-LC03: tusamitamab ravtansine versus docetaxel in pre-treated NSCLC
Benjamin Besse, MD, PhD, Gustave Roussy, Villejuif, France, discusses the results of the Phase III CARMEN-LC03 trial (NCT04154956) of tusamitamab ravtansine, an antibody-drug conjugate (ADC), in patients with advanced non-squamous non-small cell lung cancer (NSCLC) expressing high levels of CEACAM5. Patients received either tusamitamab ravtansine or docetaxel and whilst median progression-free survival (PFS) was similar between both arms, tusamitamab ravtansine showed a trend favoring overall survival. The ADC demonstrated a more favorable safety profile, with fewer severe treatment-related adverse events. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
